Safety of vaccinating sibling donors with live-attenuated varicella zoster vaccine before hematopoietic stem cell transplantation

Bone Marrow Transplantation

Volumn 39, Issue 11, 2007, Pages 661-665

  Leung, A Y H ^a   Chow, H C H ^a   Kwok, J S Y ^a   Lui, C K H ^a   Cheng, V C C ^a   Yuen, K Y ^a   Lie, A K W ^a   Liang, R ^a  

^a UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; ANTIFUNGAL AGENT; ANTIINFECTIVE AGENT; ANTINEOPLASTIC AGENT; BUSULFAN; CYCLOPHOSPHAMIDE; CYCLOSPORIN; FLUDARABINE; GAMMA INTERFERON; LIVE VACCINE; METHOTREXATE; THYMIDINE; VARICELLA ZOSTER VACCINE;

ADOLESCENT; ADULT; AGED; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; BLOOD DONOR; CELLULAR IMMUNITY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOKINE RELEASE; DRUG FATALITY; DRUG SAFETY; FEMALE; GRAFT INFECTION; GRAFT VERSUS HOST REACTION; HEMATOLOGIC MALIGNANCY; HERPES SIMPLEX; HERPES ZOSTER; HLA MATCHING; HUMAN; HUMAN CELL; HUMORAL IMMUNITY; IMMUNOMODULATION; INFECTION RISK; MAJOR CLINICAL STUDY; MALE; NONHUMAN; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; SEROLOGY; SIBLING; VARICELLA ZOSTER VIRUS; VIRUS REACTIVATION;

ADOLESCENT; ADULT; CHICKENPOX VACCINE; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HERPES ZOSTER; HUMANS; LEUKEMIA; MALE; MIDDLE AGED; SAFETY; SIBLINGS; TISSUE DONORS; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME;

EID: 34249313365     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/sj.bmt.1705673     Document Type: Article

References (14)

1. Steer CB, Szer J, Sasadeusz J, Matthews JP, Beresford JA, Grigg A. Varicella-zoster infection after allogeneic bone marrow transplantation: incidence, risk factors and prevention with low-dose aciclovir and ganciclovir. Bone Marrow Transplant 2000; 25: 657-664.
2. Leung AY, Yuen KY, Cheng VC, Lie AK, Liang R, Kwong YL. Clinical characteristics of and risk factors for herpes zoster after hematopoietic stem cell transplantation. Haematologica 2002; 87 444-446.
3. Arvin AM. Varicella-zoster virus: Pathogenesis, immunity, and clinical management in hematopoietic cell transplant recipients. Biol Blood Marrow Transplant 2000; 6: 219-230.
4. Boeckh M, Kim HW, Flowers ME, Meyers JD, Bowden RA. Long-term acyclovir for prevention of varicella zoster virus disease after allogeneic hematopoietic cell transplantation - a randomized double-blind placebo-controlled study. Blood 2006; 107: 1800-1805.
5. Hata A, Asanuma H, Rinki M, Sharp M, Wong RM, Blume K et al. Use of an inactivated varicella vaccine in recipients of hematopoietic-cell transplants. N Engl J Med 2002; 347: 26-34.
6. Vazquez M, LaRussa PS, Gershon AA, Steinberg SP, Freudigman K, Shapiro ED. The effectiveness of the Varicella vaccine in clinical practice. N Engl J Med 2001; 344: 955-960.
7. Lau GK, Lok AS, Liang RH, Lai CL, Chiu EK, Lau YL et al. Clearance of hepatitis B surface antigen after bone marrow transplantation: Role of adoptive immunity transfer. Hepatology 1997; 25: 1497-1501.
8. Bollard CM, Kuehnle I, Leen A, Rooney CM, Heslop HE. Adoptive immunotherapy for posttransplantation viral infections. Biol Blood Marrow Transplant 2004; 10: 143-155.
9. Leung AY, Suen CK, Lie AK, Liang RH, Yuen KY, Kwong YL. Quantification of polyoma BK viruria in hemorrhagic cystitis complicating bone marrow transplantation. Blood 2001; 98: 1971-1978.
10. Svahn A, Linde A, Thorstensson R, Karlen K, Andersson L, Gaines H. Development and evaluation of a flow-cytometric assay of specific cell-mediated immune response in activated whole blood for the detection of cell-mediated immunity against varicella-zoster virus. J Immunol Methods 2003; 277: 17-25.
11. Taswell C. Limiting dilution assays for the determination of immunocompetent cell frequencies. I. Data analysis. J Immunol 1981; 126: 1614-1619.
12. Levine MJ, Ellison MC, Zerbe GO, Barber D, Chan C, Stinson D et al. Comparison of a live attenuated and an inactivated varicella vaccine to boost the varicella-specific immune response in seropositive people 55 years of age and older. Vaccine 2000; 18: 2915-2920.
13. Hardy I, Gershon AA, Steinberg SP, LaRussa P. The incidence of zoster after immunization with live attenuated varicella vaccine. A study in children with leukemia. Varicella Vaccine Collaborative Study Group. N Engl J Med 1991; 325: 1545-1550.
14. Meyers JD, Flournoy N, Thomas ED. Cell-mediated immunity to varicella-zoster virus after allogeneic marrow transplant. J Infect Dis 1980; 141: 479-487.